Overwatch Research close investment round with Techstart Ventures

Overwatch Research is an innovative software company revolutionising drug development processes for pharmaceutical companies worldwide. The product reduces scientific error and inefficiencies, helping to solve the global reproducibility crisis costing $28Bn every year in the USA alone.

In the last two years, Overwatch has built a portfolio of users and partnerships on both sides of the Atlantic, helping pharmaceutical companies develop drugs for some of the world’s most prominent diseases, including cancer and Alzheimer’s.

The Techstart Ventures’ investment will enable Overwatch to expand its product offering through increased technical capability, whilst opening commercial opportunities throughout both Europe and the USA.

Overwatch CEO, Dr Chris Armstrong said: “Techstart Ventures have been crucial to our growth over the past two years due to financial support received through their proof of concept grant fund. We are delighted to take this professional relationship to the next level by having Techstart Ventures as an investor. This investment will enable us to ensure that Overwatch becomes a globally trusted solution for the pharmaceutical industry.”

Techstart Venture’s Investment Director, John Murray added: “The Overwatch solution solves problems confronting researchers and was borne out of Chris’ own experience as a cancer researcher. Chris and his co-founders, Paul and Graham Wilsdon have built a world-class product that is now being used in both Europe and the USA to help researchers ultimately find cures for disease. We’re delighted to support the Overwatch team as they enter an exciting new growth phase.”

For further information please contact Dr Chris Armstrong:

chris@overwatchresearch.com

+44 (0)7803 176659

www.overwatchresearch.com